<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778763</url>
  </required_header>
  <id_info>
    <org_study_id>BL-612-BC1</org_study_id>
    <nct_id>NCT02778763</nct_id>
  </id_info>
  <brief_title>Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis</brief_title>
  <official_title>Double Blind, Randomized, Placebo-controlled, Multicenter Pilot Study on Efficacy and Safety of CBLB612 Following Single Administration for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLab 612 LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cleveland BioLabs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioLab 612 LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, randomized, placebo-controlled, multicenter pilot study on efficacy and safety
      of CBLB612 following single administration for neutropenia prophylaxis in breast cancer
      patients receiving doxorubicin and cyclophosphamide myelosuppressive chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of ANC &lt;1.0 x 103/μl (Grade 3-4)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of ANC &lt;0.5 x 103/μl (Grade 4)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum level of ANC decrease (nadir)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to recovery of ANC level ≥1.5 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia (simultaneous drop of ANC &lt;0.5 x 103/μl and body temperature &gt;38.0°C)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation as measured by treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia &lt;50 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia &lt;25 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia &lt;10 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum decrease of platelet level (nadir)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet level recovery ≥75 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in comparison with baseline level CD34+ by FACS</measure>
    <time_frame>Baseline to up to 11 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in comparison with baseline level absolute reticulocyte count</measure>
    <time_frame>Baseline to up to 24 days after 1st the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of concentration of G-CSF by ELISA</measure>
    <time_frame>Baseline to up to 11 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>One injection of CBLB612 after Сhemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One injection of CBLB612 prior Сhemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBLB612</intervention_name>
    <description>4 μg CBLB612 SQ</description>
    <arm_group_label>One injection of CBLB612 after Сhemo</arm_group_label>
    <arm_group_label>One injection of CBLB612 prior Сhemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>One injection of CBLB612 after Сhemo</arm_group_label>
    <arm_group_label>One injection of CBLB612 prior Сhemo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBS</other_name>
    <other_name>Phosphate buffer saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent for the study participation.

          2. Women in the age above 18 years inclusively.

          3. Patients with histologically proven diagnosis of breast cancer to which the 1-st cycle
             of AC chemotherapy treatment is indicated (with 3-week interval).

          4. ECOG Performance Status of 0-2.

          5. Life expectancy ≥ 6 months.

          6. Completion of all previous cancer therapies (including surgery, radiotherapy,
             chemotherapy, immunotherapy or study therapy) not later than 4 weeks prior the CBLB612
             study.

          7. All acute toxic effects of any previous therapies &lt;Grade 1 prior the study, except for
             alopecia and/or neurotoxicity (Grade 1 or 2 is allowed).

          8. Adequate hematopoiesis function:

               -  WBC ≥3.0 x 103/μl;

               -  PTT ≥1.5 x 103/μl;

               -  Platelets ≥75 x 103/μl;

               -  Hemoglobin ≥10 g/dl.

          9. Adequate hepatic function:

               -  Total bilirubin ≤1.5 x ULN;

               -  ALT and AST ≤3 x ULN;

               -  Alkaline phosphatase ≤2.5 x ULN.

         10. Adequate renal function:

               -  Creatinine ≤1.5 x ULN.

         11. Adequate values of hemostasis system:

               -  Prothrombin time;

               -  ≤1.5 x ULN;

               -  Activated partial thromboplastin time ≤1.5 x ULN;

               -  INR ≤1.5 x ULN.

         12. Adequate cardiac function which means

               -  LVEF ≥45 based on ultrasonic examination of the heart or radionuclide
                  angiography;

               -  12-lead electrocardiogram (ECG) with normal tracing, non-clinically significant
                  changes may occur that do not require medical intervention.

         13. Negative test for serological infection markers:

               -  Negative HIV-antibody test;

               -  Negative test for hepatitis B surface antigen (HBsAg);

               -  Negative test for hepatitis C virus antibodies or negative test for mRNA of
                  hepatitis C virus;

               -  Negative test for Treponema pallidum antibodies.

         14. Negative pregnancy test.

         15. Consent of a patient with preserved reproductive function to use effective
             contraception method since screening up to at least 3 months after the study therapy.

               -  e.g. intrauterine device, oral contraceptive, subcutaneous implant or
                  double-barrier method (condom with contraceptive sponge or contraceptive vaginal
                  suppository).

         16. A patient shall be ready and able to meet the requirements of the study protocol and
             have the opportunity to participate in the study throughout the scheduled period.

        Exclusion Criteria:

          1. Rapidly progressing, clinically unstable breast cancer with present clinical signs of
             cerebral or meningeal membrane metastases.

          2. Specific contraindications or hypersensitivity data in relation to any of the
             following drugs: doxorubicin, cyclophosphamide, CBLB612, anti-emetic agents
             (aprepitant, palonosetron), anti-inflammatory drugs (including paracetamol and
             aspirin), as well excipients of the abovementioned drug agents including polysorbate
             80.

          3. History of febrile neutropenia.

          4. Presence of autoimmune disease.

          5. Acute or chronic/relapsing inflammatory eye disease or any other significant eye
             disorder.

               -  patients with mild and moderate myopia or hypermetropia, or presbyopia may be
                  enrolled to the study.

          6. Pregnancy or breast feeding, refusal to use adequate contraception methods during the
             study.

          7. Signs of ongoing systemic bacterial, fungal or viral infectious disease or local
             infection requiring treatment at the randomization.

               -  patients with local fungal lesion of skin area or nail may be enrolled to the
                  study.

          8. Systemic antibiotic therapy during up to 72 hours prior the randomization.

          9. Previous radiotherapy of ≥30% of bone marrow.

         10. Surgery or chemotherapy or experimental drug therapy within 4 weeks prior
             randomization.

         11. Transplantation of bone marrow or peripheral blood precursor cells.

         12. Intake of more than 10 portions of alcoholic beverages per week or anamnestic data on
             alcoholism, narcomania, drug abuse.

               -  one portion of alcoholic beverage is 250 ml of beer, 125 ml of wine or 30 ml of
                  strong alcoholic beverage.

         13. Current immunosuppressant therapy including systemic corticosteroid therapy.

         14. Clinically significant abnormal vital signs, results of laboratory and instrumental
             tests, based on the investigator assessment.

         15. Any disease, condition, organ dysfunction or central nervous system disorder of the
             intake of narcotic drugs which, according to the investigator, may affect ability to
             participate in the study or hinder assessment of study results.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergei A. Tiuliandin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution &quot;Russian Oncological Research Center named after N. N. Blokhin&quot; of the Russian Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleksei G. Manikhas, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.-Petersburg State Budgetary Healtcare Institution &quot;City Clinical Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitrii A. Krasnozhon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budgetary Healtcare Institution &quot;Leningrad Region Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruslan M. Paltuev, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Non-State Healtcare Institution &quot;Road Clinical Hospital of Open Joint Stock Company Russian Railways&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia V. Fadeeva, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Healtcare Institution &quot;Chelyabinsk Regional Clinical Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roman S. Ponomarev, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Region Budgetary Healtcare Institution &quot;Murmansk Region Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <link>
    <url>http://www.cbiolabs.com/cblb612</url>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>TLR2</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

